179 related articles for article (PubMed ID: 38593226)
1. CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
Archer S; Brailey PM; Song M; Bartlett PD; Figueiredo I; Gurel B; Guo C; Brucklacher-Waldert V; Thompson HL; Akinwale J; Boyle SE; Rossant C; Birkett NR; Pizzey J; Maginn M; Legg J; Williams R; Johnston CM; Bland-Ward P; de Bono JS; Pierce AJ
Clin Cancer Res; 2024 Apr; 30(8):1595-1606. PubMed ID: 38593226
[TBL] [Abstract][Full Text] [Related]
2. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
[TBL] [Abstract][Full Text] [Related]
3. BT7480, a novel fully synthetic
Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
[TBL] [Abstract][Full Text] [Related]
4. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
5. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
[TBL] [Abstract][Full Text] [Related]
6. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
[TBL] [Abstract][Full Text] [Related]
7. Fully human antibody V
Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
[TBL] [Abstract][Full Text] [Related]
8. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
[TBL] [Abstract][Full Text] [Related]
9. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
[TBL] [Abstract][Full Text] [Related]
10. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
Upadhyaya P; Lahdenranta J; Hurov K; Battula S; Dods R; Haines E; Kleyman M; Kristensson J; Kublin J; Lani R; Ma J; Mudd G; Repash E; Van Rietschoten K; Stephen T; You F; Harrison H; Chen L; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500260
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
Glez-Vaz J; Azpilikueta A; Olivera I; Cirella A; Teijeira A; Ochoa MC; Alvarez M; Eguren-Santamaria I; Luri-Rey C; Rodriguez-Ruiz ME; Nie X; Chen L; Guedan S; Sanamed MF; Perez Gracia JL; Melero I
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236742
[TBL] [Abstract][Full Text] [Related]
12. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.
Lim EA; Schweizer MT; Chi KN; Aggarwal R; Agarwal N; Gulley J; Attiyeh E; Greger J; Wu S; Jaiprasart P; Loffredo J; Bandyopadhyay N; Xie H; Hansen AR
Clin Genitourin Cancer; 2023 Jun; 21(3):366-375. PubMed ID: 36948922
[TBL] [Abstract][Full Text] [Related]
14. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
15. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
17. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
Liu G; Luo P
Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
20. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
Sheehan B; Neeb A; Buroni L; Paschalis A; Riisnaes R; Gurel B; Gil V; Miranda S; Crespo M; Guo C; Jiménez Vacas J; Figueiredo I; Ferreira A; Welti J; Yuan W; Carreira S; Sharp A; de Bono J
Clin Cancer Res; 2022 Jul; 28(14):3104-3115. PubMed ID: 35552383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
